胸腺素联合单磷酸阿糖腺苷治疗慢性乙型重型肝炎24例  

Clinical Effect of Thymosin Combined with Vidarabine on 24 Cases of Chronic Severe Hepatitis B Treatment

作　　者：李国军[1] 王卫华[1] 李洪涛[1] 覃惠敏[1] 吴春明[1] 宋建新[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院感染科

出　　处：《医药导报》2005年第9期788-790,共3页Herald of Medicine

摘　　要：目的观察胸腺素联合单磷酸阿糖腺苷治疗慢性乙型重型肝炎的疗效。方法慢性重型乙型肝炎46例,分成治疗组24例,对照组22例。对照组采用磷酸阿糖腺苷等支持、保肝疗法;治疗组在此基础上加胸腺素1.6mg,sc,qd,20d后改为每周2次,共8周。检测血清总胆红素(T-BiL)、丙氨酸氨基转氨酶(ALT)、凝血因子II活动度(PTA)、内毒素、白细胞介素类及T细胞亚群(CD4+T细胞,CD8+T细胞)。结果治疗组总有效率71.0%,病死率29.0%;对照组总有效率41.0%,病死率59.0%,两组比较差异有显著性(P<0.05);治疗组治疗后各项生化指标均优于对照组(P<0.05)。结论胸腺素联合单磷酸阿糖腺苷治疗重型肝炎能减轻肝脏的免疫性损伤,降低病死率,无明显不良反应,治疗重型肝炎安全、有效。Objective To observe the clinical efficacy of thymosin α1 （Tα1） combined with vidarabine on chronic severe hepatitis. Methods Forty-six chronic severe hepatitis B patients were divided into the treatment group （n=24） and the control group （n=22）. The control group were treated with vidarabine, and the treatment group with Tα1 and vidarabine for 8 wk. The serum levels of total bilirubin （T-BiL）, alanine aminotransferase （ALT）, plasma thromboplastin activity （PTA）, endotoxin, interleukin and T-lymphocyte subsets were compared. Results The total effective rate and mortality in treatment group were 71.0% , 29.0% , and in the control group were 41.0% , 59.0%. There was a significant difference between the two groups （ P〈0.05 ）. Conclusion Tα1combined with vidarabine can lessen the harm of liver function by immune reaction and lower the mortality of chronic severe hepatitis B.

关 键 词：胸腺素 单磷酸阿糖腺苷 肝炎 重型 乙型 慢性 

分 类 号：R979.5[医药卫生—药品] R512.62[医药卫生—药学]